INC.

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting

by

In the ASCO Developmental Therapeutics – Immunotherapy Session, Dr. Howard Safran presents encouraging data on Dragonfly’s phase 1/2 study of DF1001, an immune engaging TriNKET® targeting HER2 in patients with advanced solid tumors. WALTHAM, Mass., June 5, 2023 /PRNewswire/ — Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of … Read more

Illumina releases 2022 Corporate Social Responsibility Report

by

SAN DIEGO, June 5, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its annual Corporate Social Responsibility (CSR) Report, highlighting the company’s commitment to human health, and the progress made by its environmental, social, and governance (ESG) program in 2022. Today, Illumina announced its annual … Read more

Celsius Holdings, Inc. to Present at Upcoming June Investor Conferences

by

STIFEL 2023 Cross Sector Insight Conference – June 6, 2023Evercore ISI 3rd Annual Consumer and Retail Conference – June 14, 2023Jefferies Consumer Conference – June 20-21, 2023 BOCA RATON, Fla., June 5, 2023 /PRNewswire/ — Celsius Holdings, Inc., (Nasdaq: CELH), maker of the leading global fitness drink, CELSIUS®, today announced the company will present at upcoming … Read more

Conformal Medical Raises $35 Million in Oversubscribed Series D Round

by

The round was led by SPRIG Equity with participation from all major Series C investors NASHUA, N.H., June 5, 2023 /PRNewswire/ — Conformal Medical, Inc., a medical device company developing next-generation left atrial appendage occlusion (LAAO) technology, today announced the successful completion of its Series D funding round, raising a total of $35 million. Conformal Medical’s CLAAS® Implant (PRNewsfoto/Conformal Medical, Inc.) “SPRIG Equity is focused on enabling transformative medical technology companies to achieve … Read more

BIOLASE Takes Steps to Improve Operating Efficiency as the Company Pursues Sales and Profitability Goals

by

LAKE FOREST, Calif., June 5, 2023 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), a global leader in dental lasers, is taking the necessary steps to optimize operations to capitalize on the rising business momentum for its market-leading dental lasers. The Company believes its revenue-generating strategies and prudent management of its expenses, combined with the completion of its recent … Read more

Home Healthcare Market to Hit $666.9 Billion by 2030: Grand View Research, Inc.

by

SAN FRANCISCO, June 5, 2023 /PRNewswire/ — The global home healthcare market size is expected to reach USD 666.9 billion by 2030, according to a report by Grand View Research, Inc., expanding at a CAGR of 7.96% over the forecast period. This growth can be attributed to cost-efficiency, improved patient outcomes, and convenience offered by home … Read more

NUTEX HEALTH TO PRESENT AT THE STIFEL 2023 CROSS SECTOR INSIGHT CONFERENCE ON JUNE 7 IN BOSTON

by

HOUSTON, June 5, 2023 /PRNewswire/ — Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 19 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced that Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health is scheduled to … Read more

SOUTH JERSEY BEHAVIORAL HEALTH RESOURCES PROVIDES NOTICE OF DATA PRIVACY EVENT

by

PENNSAUKEN, N.J., June 4, 2023 /PRNewswire/ — On April 5, 2023, South Jersey Behavioral Health Resources (“SJBHR”) discovered encrypted files on certain computer systems.  SJBHR immediately launched an investigation, with the assistance of third-party forensic specialists, to determine the nature and scope of the activity.  The investigation determined that there was unauthorized access to certain of its … Read more

Dragonfly Therapeutics présentera les résultats de la phase 1 de la monothérapie DF1001 à l’occasion du congrès annuel de l’ASCO 2023

by

Une présentation orale intitulée « Phase 1/2 Study of DF1001, an Immune Modulating TriNKET® Targeting HER2, in Patients with Advanced Solid Tumors: Phase 1 DF1001 Monotherapy Dose Escalation Results » sera présentée par Howard Safran, directeur médical, lors de la session ASCO Developmental Therapeutics – Immunotherapy le 4 juin. WALTHAM, Mass., 3 juin 2023 /PRNewswire/ — Dragonfly Therapeutics, Inc, une société … Read more

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

by

–  PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint blockade with prolonged duration of responses – –  Recurrent/metastatic HPV-associated cancers (cervical, anal, oropharyngeal, etc.) are incurable by current therapies – –  PRGN-2009 was safe and well-tolerated with only Grade … Read more